journal article·2022-01-12

Self-Deliverable Peptide-Mediated and Reactive-Oxygen-Species-Amplified Therapeutic Nanoplatform for Highly Effective Bacterial Inhibition

Rong Huang, Qi-Hang Yu, Xue-Di Yao, Wen-Long Liu, Yin-Jia Cheng, Yi-Han Ma, Ai-Qing Zhang, Si-Yong Qin

Publisher page

Abstract

An “antibiotic-free strategy” provides a viable option to address bacterial infections, especially for the “superbug” challenge. However, the undesirable antibacterial activity of antibiotic-free agents hinders their practical applications. In this study, we developed a combination antibacterial strategy of coupling peptide-drug therapy with chemodynamic therapy (CDT) to achieve the effective bacterial inhibition. An amphiphilic oligopeptide (LAOOH-OPA) containing a therapeutic unit of D(KLAK)2 peptide and a hydrophobic linoleic acid hydroperoxide (LAHP) was designed. The positively charged D(KLAK)2 peptide with an α-helical conformation enabled rapid binding with microbial cells via electrostatic interaction and subsequent membrane insertion to deactivate the bacterial membrane. When triggered by Fe2+, moreover, LAHP could generate singlet oxygen (1O2) to elicit lipid bilayer leakage for enhanced bacteria inhibition. In vitro assays demonstrated that the combination strategy possessed excellent antimicrobial activity not only merely toward susceptible strains (Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli) but also toward methicillin-resistant Staphylococcus aureus (MRSA). On the mouse skin abscess model induced by S. aureus, self-assembled LAOOH-OPA exhibited a more significant bacteria reduction (1.4 log10 reduction) in the bioburden compared to that of the standard vancomycin (0.9 log10 reduction) without apparent systemic side effects. This combination antibacterial strategy shows great potential for effective bacterial inhibition.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan 430074, P. R. China

Key Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science, South Central University for Nationalities, Wuhan 430074, China

Funding

Ministry of Education of the People's Republic of China · South-Central University for Nationalities · National Natural Science Foundation of China · Key Laboratory of Biomedical Polymers of Ministry of Education, Wuhan University

References (57)

Show source-provided references
1. 10.1002/adma.20207013810.1002/adma.202070138 ↗
2. 10.1016/j.biomaterials.2020.11997210.1016/j.biomaterials.2020.119972 ↗
3. 10.1016/S1473-3099(20)30327-310.1016/S1473-3099(20)30327-3 ↗
4. 10.1016/j.colsurfb.2021.11168210.1016/j.colsurfb.2021.111682 ↗
5. 10.1016/j.bcp.2016.09.01810.1016/j.bcp.2016.09.018 ↗
6. 10.1039/D0CS01026J10.1039/D0CS01026J ↗
7. 10.1038/nnano.2009.15310.1038/nnano.2009.153 ↗
8. 10.1021/acsami.7b0750610.1021/acsami.7b07506 ↗
9. 10.1021/acs.biomac.8b0174010.1021/acs.biomac.8b01740 ↗
10. 10.1126/sciadv.aaz476710.1126/sciadv.aaz4767 ↗
11. 10.1039/D0BM00789G10.1039/D0BM00789G ↗
12. 10.1002/anie.20190734310.1002/anie.201907343 ↗
13. 10.1002/adhm.20190060810.1002/adhm.201900608 ↗
14. 10.1016/j.dyepig.2019.10794810.1016/j.dyepig.2019.107948 ↗
15. 10.1039/D1TB00868D10.1039/D1TB00868D ↗
16. 10.1021/acsnano.0c0525510.1021/acsnano.0c05255 ↗
17. 10.1002/adfm.20210024310.1002/adfm.202100243 ↗
18. 10.1002/anie.20170118110.1002/anie.201701181 ↗
19. 10.1021/jacs.0c0560410.1021/jacs.0c05604 ↗
20. 10.1021/la203518w10.1021/la203518w ↗
21. 10.1039/C8CC09548E10.1039/C8CC09548E ↗
22. 10.1021/acsami.0c0941410.1021/acsami.0c09414 ↗
23. 10.1016/j.impact.2017.11.00410.1016/j.impact.2017.11.004 ↗
24. 10.1021/acsbiomaterials.1c0045710.1021/acsbiomaterials.1c00457 ↗
25. 10.1002/adma.20180200610.1002/adma.201802006 ↗
26. 10.1016/j.thromres.2020.07.02710.1016/j.thromres.2020.07.027 ↗
27. 10.3390/ph1306013310.3390/ph13060133 ↗
28. 10.1016/j.jgeb.2017.02.01010.1016/j.jgeb.2017.02.010 ↗
29. 10.1016/j.memsci.2019.11764110.1016/j.memsci.2019.117641 ↗
30. 10.1021/acscentsci.9b0035910.1021/acscentsci.9b00359 ↗
31. 10.1021/acs.chemmater.0c0205510.1021/acs.chemmater.0c02055 ↗
32. 10.1002/cnma.20190054910.1002/cnma.201900549 ↗
33. 10.1021/acsnano.9b0431510.1021/acsnano.9b04315 ↗
34. 10.1007/s12161-019-01499-310.1007/s12161-019-01499-3 ↗
35. 10.1039/C5NR03862F10.1039/C5NR03862F ↗
36. 10.1039/C8TB03094D10.1039/C8TB03094D ↗
37. 10.1002/anie.20070086110.1002/anie.200700861 ↗
38. 10.1039/c3sm52730a10.1039/c3sm52730a ↗
39. 10.1021/ar600050710.1021/ar6000507 ↗
40. 10.1038/nrmicro.2017.2610.1038/nrmicro.2017.26 ↗
41. 10.1073/pnas.190173011610.1073/pnas.1901730116 ↗
42. 10.1016/j.actbio.2020.02.03610.1016/j.actbio.2020.02.036 ↗
43. 10.1021/acs.molpharmaceut.7b0043410.1021/acs.molpharmaceut.7b00434 ↗
44. 10.1021/jacs.9b0716210.1021/jacs.9b07162 ↗
45. 10.1089/mdr.2017.039210.1089/mdr.2017.0392 ↗
46. 10.1016/j.jid.2020.04.01210.1016/j.jid.2020.04.012 ↗
47. 10.1099/jmm.0.00116310.1099/jmm.0.001163 ↗
48. 10.1073/pnas.110108910810.1073/pnas.1101089108 ↗
49. 10.1016/j.biomaterials.2020.12034110.1016/j.biomaterials.2020.120341 ↗
50. 10.1039/D0NR00181C10.1039/D0NR00181C ↗
51. 10.1021/acsami.9b1774710.1021/acsami.9b17747 ↗
52. 10.1093/jac/dks37910.1093/jac/dks379 ↗
53. 10.1016/j.jconrel.2011.07.00210.1016/j.jconrel.2011.07.002 ↗
54. 10.1021/acsami.0c1235510.1021/acsami.0c12355 ↗
55. 10.1002/smll.20150195810.1002/smll.201501958 ↗
56. 10.1021/nn300838310.1021/nn3008383 ↗
57. 10.1016/j.cell.2007.06.04910.1016/j.cell.2007.06.049 ↗